24/7 Market News Snapshot 04 August, 2025 – INmune Bio Inc. Common stock (NASDAQ:INMB)

August 4, 2025

DENVER, Colo., 04 August, 2025 (www.247marketnews.com) – (NASDAQ:INMB) are discussed in this article.
INmune Bio Inc. has recently emerged as a notable player in the biotech industry, exemplified by a significant surge in its stock price and the successful results of its Phase I/II clinical trial. The company’s stock climbed 27.54% in pre-market trading, reaching $3.265, reflecting a strong investor interest fueled by promising developments surrounding its product, INKmune™. This stock surge comes alongside robust trading activity, indicating heightened market confidence in the company’s future prospects.

Crucially, INmune Bio has announced that its CaRe PC trial, which investigated INKmune™ for metastatic castration-resistant prostate cancer (mCRPC), has met its primary and secondary endpoints. The trial results demonstrate a strong safety profile for INKmune™ across all tested dosage levels, showcasing its ability to activate natural killer (NK) cells—key elements of the immune system adept at targeting tumors. Notably, patients exhibiting low NK cell activation showed marked improvements in their biomarkers, which may assist in identifying optimal candidate populations for subsequent studies.

As the company looks to the future, it plans to launch a randomized Phase 2b trial to further evaluate INKmune™ in patients with less advanced disease. Such a trial is expected to yield valuable insights into the treatment’s efficacy and potential benefits for a wider range of patients.

INKmune™ stands out as an innovative immunotherapy that enhances the immune response against various cancers without the need for pre-treatment medications, administering via outpatient intravenous infusion. INmune Bio is committed to leveraging the body’s innate immune capabilities to deliver transformative therapies against chronic inflammation and cancer, underscoring its role in advancing healthcare solutions.

Related news for (INMB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.